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Figure 1 
All matched significant pathways (p<0.05) from the pilot run are represented by circles, 
with the color of each circle corresponding to its p-value (y axis) and the size of the circle 
corresponding to its pathway impact value (x axis). The pathway impact depends on the 
number of metabolites that are seen in a specific metabolic pathway.  27 
  
Figure 2 
All matched significant pathways (p<0.05) from the untargeted RPLC and HILIC coupled 
with tandem MS are represented by circles, with the color of each circle corresponding to 
its p-value (y axis) and the size of the circle corresponding to its pathway impact value (x 
axis). The pathway impact depends on the number of metabolites that are seen in a specific 
metabolic pathway.         28 
 
Figure 3 
Volcano plots representing comparisons among predetermined groups having occurred 
from the RPLC-MS (untargeted). 3A Comparison of H/H vs. D/D. 3B Comparison of H/H 
vs. H/D. 3C Comparison of D/D vs. H/D 
In the volcano plots each compound, identified and unidentified, is represented by a single, 
colored circle. The circles are colored pink, if the false discovery rate (FDR) is <5%, green 
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if FDR=5-20% and yellow if FDR >20%. The identified metabolites have their names 
written by their assigned circle. Most circles with FDR <5% were not identified. This 
indicates the need for a targeting approach. 
(H/H): healthy sites in healthy subjects; (D/D): diseased sites in diseased subjects;  
(H/D): healthy sites in diseased subjects      31 
 
Figure 4 
Volcano plots representing comparisons among predetermined groups having occurred 
from the HILIC-MS (untargeted). 4A Comparison of H/H vs. D/D. 4B Comparison of H/H 
vs. H/D. 4C Comparison of D/D vs. H/D 
In the volcano plots each compound, identified and unidentified, is represented by a single, 
colored circle. The circles are colored pink, if the false discovery rate (FDR) is <5%, green 
if FDR=5-20% and yellow if FDR >20%. The identified metabolites have their names 
written by their assigned circle. Most circles with FDR <5% were not identified. This 
indicates the need for a targeting approach. 
(H/H): healthy sites in healthy subjects; (D/D): diseased sites in diseased subjects;  





(A) Heatmap representing the detected compounds in sampled sites from the selected 20 
subjects. In the heatmap. The red color represents low levels of a metabolite and the blue 
high levels of a metabolite. (B) PLS-DA: Representation of each patient and the individual 
sampled sites. 
(H/H): healthy sites in healthy subjects (blue circle) 
(D/D): diseased sites in diseased subjects (red circle) 
(H/D): healthy sites in diseased subjects (green circle)    39 
 
Figure 6 
Volcano Plots of the baseline cross-sectional analysis by NMR 6A Comparison of H/H vs. 
D/D. 6B Comparison of H/H vs. H/D. 6C Comparison of D/D vs. H/D 
In the volcano plots each compound is represented by a single, dot. The dots are colored 
black if the FDR is <5% and white if FDR >5%. The identified metabolites have their 
names written by their assigned dot. 
(H/H): healthy sites in healthy subjects 
(D/D): diseased sites in diseased subjects 







Longitudinal (yearly) changes in metabolites with 95% confidence interval. Left column 
presents the untreated sites and the right column presents the treated sites. These results 
have been a part of the NMR analysis. The dots are colored red if the FDR is <20% and 
grey if FDR >20%. 
(H/H): healthy sites in healthy subjects 
(D/D): diseased sites in diseased subjects 






Periodontitis’ Definition and Prevalence 
Periodontitis is characterized by microbially-associated, host-mediated 
inflammation which results in loss of periodontal attachment (Tonetti et. al. 2018). This 
is identified in the form of clinical attachment loss (CAL) in the existing dentition, 
measured from the cemento-enamel junction (CEJ) as a reference point to the tip of a 
periodontal probe during periodontal diagnostic probing. Severe periodontitis is the 6th 
most prevalent disease in the world (Kassebaum 2014). According to estimates, the 
prevalence of periodontitis during the years 2009-2014 was reported as 42% for dentate 
American adults over 30 years old (approximately 65 million adults), with 7.8% having 
severe periodontitis (Eke et. al. 2012, 2018). The case definition of periodontitis in the 
above study included all cases that have ≥2 interproximal sites with CAL ≥3 mm and ≥2 
interproximal sites with pocket depth (PD) ≥4 mm (not on the same tooth) or one site with 
PD ≥5 mm (Eke et. al. 2012).  
However, for the purposes of this manuscript, the periodontitis case definition 
reported in the 2018 Workshop for a new classification of Periodontal and Peri-implant 
Diseases and Conditions is used: presence of interdental CAL detectible at ≥ 2 non-adjacent 
teeth, or buccal or oral CAL ≥ 3 mm with pocketing > 3 mm is detectible at ≥ 2 teeth 
(Tonetti et. al. 2018). Excluded are sites of recession originating from trauma, cervical 
dental caries, CAL on the distal site of 2nd molars potentially related to malposition or a 3rd 
molar extraction, an endodontic lesion that is draining through the gingival margin and the 
presence of a vertical root fracture. 
Diagnosis and Prognosis of Periodontal Disease 
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Armitage in 1999 proposed a classification of periodontal diseases (Armitage 
1999). He classified periodontitis into chronic, aggressive, periodontitis as a manifestation 
of systemic diseases and necrotizing periodontal disease. He subdivided chronic and 
aggressive periodontitis into localized and generalized and assigned three categories of 
severity: slight, moderate and severe. The most recent classification of periodontal 
conditions by the 2018 Workshop identified necrotizing periodontitis, periodontitis as a 
manifestation of systemic diseases and periodontitis. Periodontitis was subdivided into 
Stages I to IV, according to severity and according to the rate of progression into Grade A 
to C, thus eliminating the category of Aggressive Periodontitis of the previously mentioned 
classification (Papapanou 2018). This study focuses on severe chronic and aggressive 
periodontitis, according to the Armitage classification, and Stages III and IV Periodontitis, 
according to the Papapanou classification, with CAL loss of 5 mm or more. 
Additionally, whereas several prognosis classifications exist (McGuirre 1996, 
Kwok & Caton 2007, Martin 2009), definitive and accurate predictors to integrate into 
the treatment plan have still not been identified (Nunn 2012). The high negative predictive 
value of bleeding on probing (BOP) – absence of BOP indicates periodontal stability – 
makes it a good predictor for disease progression (Lang 1990). 
Currently, there is no accurate way to predict the initiation and progression of 
periodontal disease. Thus, clinicians do not differentially treat periodontitis, according to 
susceptibility to risk of future disease. This is inefficient and expensive as an approach and 
it leads to unnecessary treatment for multiple patients. In 2011 alone, the cost of 
periodontal treatment in the U.S. approximated 50 billion dollars (Flemmig 2013). In 2015, 
in the dental field, the greatest losses in productivity were attributed to tooth loss ($126.67 
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billions – 67%), with an additional $38.85 billion (21%) to severe periodontitis (Righolt 
2018). This is the reason why it is crucial to develop a site-specific prognostic test to predict 
future periodontal disease initiation and/or progression. 
Development of a Test in “-omics” Era 
Periodontitis’ diagnosis is currently based on the use of the periodontal probe which 
is utilized to measure the depth of dento-gingival sulcus in millimeters (mm) and the extent 
of CAL. This is a rather rudimentary tool, which is very uncomfortable for the patient and 
identifies periodontitis after it has developed.  It also entails measurement error (±1mm) 
by the examiner (Watts 1995). For reference, a change of 2 mm in the depth of the pocket, 
which is considered disease progression in a 12-14 mm-long root of the tooth; thus, the 
periodontal probe’s lack of consistency is emphasized. Various contemporary tests for 
periodontitis have been developed that measure periodontal microorganisms, proteins and 
enzymes in the periodontal pocket (Armitage 2003). While these tests may provide 
interesting information regarding periodontitis in a specific individual, their use in the 
clinical setting has not been yet validated. 
The most promising field of studies for the development of an appropriate 
diagnostic test for periodontitis onset and progression is the “-omics” field. Also referred 
in the literature as “multi-omics”, this field allows not only for diagnosis and detection of 
the disease, but also for differentiating among its various stages and determination of 
treatment outcomes, acting as “tools” for understanding the dynamics of periodontal 
disease progression (Callif 2017). 
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According to a recent review, the data obtained by the use of “-omics” technologies 
have great potential to inform paradigm shifts in our understanding of periodontal diseases, 
but data management, analysis and interpretation are to be done with systematic 
bioinformatics approach, to reach meaningful conclusions (Grant 2012). The genomic 
investigations aim to study the genome. They have succeeded in finding the most important 
susceptibility loci responsible for periodontitis. The number of genetic loci associated with 
periodontal disease obtained from genomic studies of aggressive and chronic periodontitis 
is increasing (Morelli 2020). Few loci, mainly identified for aggressive and severe forms 
of the disease, have been replicated and reached statistical significance. Most of the 
genomic studies in periodontitis have small or moderate sample sizes and are very 
heterogenous in their methods and reported results. 
Along with genomics, transcriptomics aims to find specific genes and single 
nucleotide polymorphisms which are associated with an increased risk to develop 
periodontitis, as well as to detect differences in gene expression in periodontitis-affected 
individuals. Usually, genomic and transcriptomic studies have been focusing on one or 
limited candidate genes/transcripts. In other studies, genome- or transcriptome-wide 
approaches have been carried out, omitting an a priori positive discrimination of certain 
genes. These studies require the extraction of DNA or RNA from blood, epithelial cells 
collected from an oral swab, gingival tissue, among other sources. In these studies, classical 
inflammatory mediators have been identified (Trindale 2014). 
The aim of proteomics is the evaluation of the complete protein and peptide in 
health and periodontitis. It includes the technological applications to identify and quantify 
the sum of proteins existing in cells, tissues of an organism. Proteomics is able to analyze 
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and categorize the overall protein signature tracing all the way back to the genome. 
Technological applications involving proteomics are used in many branches of research 
involving diagnostic markers’ detection, production of vaccines, pathogenesis mechanisms 
comprehension, understanding of the protein pathways in various diseases (Aslam 2016). 
The most recent studies, however, focus on metabolomics, which has not yet been 
studied in equal detail to the previous three branches of the multi-omics (Veensra 2012). 
Referring back to model of genomics, transcriptomics, proteomics and metabolomics, our 
greatest chance in finding meaningful periodontitis biomarkers will be analyses that report 
correlations at all four levels. Metabolomics has gained popularity since it profiles directly 
the phenotype and changes thereof in contrast to other “-omics” technologies (Amberg 
2017). Metabolomics’ ultimate aim is to obtain a complete screen of all the metabolites of 
a given biological sample and interpret how the metabolic profile changes with a given 
pathophysiological state.  
However, the technology to study metabolomics only recently reached its peak. The 
main techniques to study metabolomics are Mass Spectrometry (MS) and Nuclear 
Magnetic Resonance (NMR) spectroscopy. NMR and MS both have their own advantages 
and disadvantages in conduction of metabolomic studies. MS’s greatest advantage is its 
high sensitivity, being able to identify hundreds of species in a single sample. The test’s 
sensitivity allows the identification of multiple compounds with rare false positive results. 
One of the main weakness of MS is quantification. The MS signal intensity of any 
compound is affected by the type of sample preparation used and efforts to correct for that 
can lead to inaccuracy and imprecision (Veenstra 2012). MS entails a high level of bias, 
requires multiple steps for preparation, it is only moderately reproducible and is destructive 
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(Emwas 2015). The major weaknesses of MS are the advantages of NMR. NMR is very 
precise and non-biased. It requires fewer steps than MS to be conducted, it is non-
destructive and very reproducible. However, it has low sensitivity. It is obvious, thus, that 
these two procedures are completing each other’s weaknesses. 
Studies on the Diagnostic Value of Saliva for Periodontitis 
 There have been multiple studies that have investigated the existing salivary 
metabolites that are used as diagnostic tools. Tongue swabs and saline washouts have been 
also able to identify metabolites that are related to health and disease through NMR 
analysis (Gawron 2019). Additionally, the salivary metabolic fingerprints, through NMR, 
of chronic and aggressive periodontitis have been studied with no significant differences 
between the two conditions (Romano 2018). 
Identified salivary metabolites associated with periodontal disease are the 
dipeptides leucylisoleucine, phenylphenol, and serylisoleucine as well as the fatty acids 
arachidonate, arachidate, and dihomo-linolate are attractive candidate markers (Barnes 
2011). Another study reported increased concentration of acetate, c-aminobutyrate, n-
butyrate, succinate, trimethylamine, propionate, phenylalanine and valine in chronic 
periodontitis subjects and reduced pyruvate and N-acetyl groups compared to periodontal 
health (Aimetti 2012). 
A recent systematic review on metabolomics investigating saliva samples reached 
the conclusion that valine, phenylalanine, isoleucine, tyrosine and butyrate are increased 
in periodontitis-affected subjects, whereas lactate, pyruvate and N-acetyl groups were 
increased in periodontally healthy patients (Baima 2021).  
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Other salivary metabolites positively associated with increased PDs are: caproate, 
isocaproate/butyrate, isovalerate, isoleucine, isopropanol/methanol, 4-aminobutyrate, 
choline, sucrose, sucrose/glucose/lysine, lactate/proline, lactate and proline (Garcia-
Villaescusa 2018). The bacterial metabolite phenylacetate isolated from saliva has been 
significantly associated with periodontitis (Liebsch 2019). 
From the data of another systematic review, several biomarkers have been assessed 
in the literature for their sensitivity and specificity in diagnosing periodontitis. However, 
there is no assessment of sensitivity and specificity in metabolomics studies. MΙP-1α, IL-
6, IL-1β and MMP-8 were acceptable. The combination of IL-6 and MMP-8 showed the 
most promising diagnostic accuracy. However, the studies included in the literature review 
are very heterogenous and the results need to be cautiously interpreted (KC 2020). 
In another systematic review and meta-analysis, MMP8, MMP9, IL-1β, IL6 and 
hemoglobin in saliva were indicated as the biomarkers with the ability to detect 
periodontitis in medically healthy subjects. The highest sensitivity to detect periodontitis 
was attributed to IL-1β and the highest specificity for MMP-9 81.5% (Arias-Bujanda 
2020). 
Studies on the Prognostic Value of Saliva for Periodontitis 
Other studies have looked into the predictive value of salivary metabolites 
concerning periodontitis development and progression. Cadaverine, 5-oxoproline, and 
histidine have been shown to be metabolites isolated in saliva that are associated with 
periodontitis and could potentially predict the onset or progression of that disease 
(Kuboniwa 2016).  
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Furthermore, an NMR-based study showed that non-surgical periodontal treatment 
is able to lead to significant changes in the salivary metabolic profile of a periodontitis 
patient, however it will still be distinct from the one of a healthy patient (Romano 2019, 
Citterio 2020).  
Studies on the Diagnostic Value of Gingival Crevicular Fluid for Periodontitis 
One of the most promising oral fluid that is rich in biomarkers is the gingival 
crevicular fluid (GCF). The GCF is a biologic fluid and inflammatory exudate that 
originates from the blood vessels in the connective tissue of the gingiva, which is sub-
adjacent to the epithelial lining of the dento-gingival space (Barros et. al 2016). The 
literature suggests that GCF from clinically healthy tissue is an altered serum transudate, 
which becomes inflammatory exudate in the presence of periodontitis and gingivitis. 
Additionally, GCF has a different microbial profile; the concentration and composition of 
molecular biomarkers between health and disease can be used to predict patient-based and 
site-based outcomes. Whereas, saliva is more readily available compared to GCF, the latter 
has the advantage that it can reveal data on the metabolic profile on periodontitis in a site-
specific way. This could predict changes on a site-level that may occur to the periodontium 
in the future, prior to the onset or the progression of the disease, thus avoiding periodontal 
breakdown in terms of CAL loss, PD increase, bone loss, mobility and eventually tooth 
loss. 
GCF has been introduced as a diagnostic aid, using its flow and contents, since the 
70s (Golub 1976, Smith 1977). There are currently more than 90 elements found in the 
GCF that may be of use as diagnostic and/or prognostic markers. Those elements include 
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inflammatory mediators, markers of oxidative stress, host-derived enzymes, tissue-
breakdown products and mediators of bone homeostasis (Ghallab 2018).  
There has been a series of studies that focused on antibodies in the GCF as 
diagnostic biomarkers for periodontitis. It has been proven that immunoglobulins can be 
detected in GCF and, in certain sites, they are in even greater levels than in serum, which 
supports the concept of specific local antibody synthesis in gingival tissues (Ebersole 
1984, Smith 1985). In a follow-up study of the same group, the elevated antibody levels 
were correlated with responses to specific periodonto-pathogenic bacteria 
(Aggregatibacter actionomycetemcomitans, Porphyromonas gingivalis and Bacteroides 
intermedius) (Ebersole 1985). 
Weak association has been found between the myeloperoxidase (MOP) in the GCF 
and clinical measurements of periodontal disease, but the concentration of it is higher in 
the diseased sites; however, GCF’s MPO previously observed at periodontitis sites is not 
specific to such sites. The increase of MPO in GCF likely occurs when additional 
polymorphonuclear leukocytes (PMNs) enter the sulcus as a result of gingival 
inflammation (Smith 1986, Cao 1989).  
Neutrophil elastase (NE) is another enzyme that is elevated in the GCF in 
periodontitis patients. The increase NE available in PMNs compared to NE inhibitors in 
GCF suggest that there is a transient increase in free NE, which leads to tissue destruction 
(Smith 1994, Smith 1995).  
The glycosamynoglycans chondroitin-4-sulphate and hyaluronan have been 
reported to be elevated in periodontitis and to be reduced with periodontal treatment; thus, 
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they may be used as diagnostic markers for periodontitis (Smith 1995, Smith 1997). 
Proteoglycans metabolism, as analyzed by the determination of uronic acids in GCF, did 
not seem to significantly affect clinical measurements (Huri 2003).  
In the 1990s, Smith is the one that starts to look into GCF proteomics in a site-
specific way. In a study looking at lactate dehydrogenate (LDH), aryl sulfate (AS) and NE, 
all varied from sampling to sampling. However, the differences among sites were retained 
throughout the length of the experimental period (Smith 1991). It seems that the previously 
mentioned MOP is one of the most useful enzymes as biochemical marker for severe 
periodontal disease in a site-specific manner (Smith 1992). It is important to select 
representative surfaces in the mouth and for that reason, multiple studies, including this 
one, have pre-selected the Ramfjord teeth for sampling (Ramfjord 1967) 
Multiple studies have aimed at the characterization of the GCF proteome 
identifying between 199 (Carneiro 2012) and 327 (Tsuchida 2012) proteins in 
periodontally healthy sites. Other studies, have demonstrated a comparison between 
periodontally healthy and diseased sites. In a study by Kido in 2012, using Mass 
Spectrometry it was shown that 64 proteins were observed only in healthy sites, while 63 
proteins were observed in diseased sites (Kido 2012). 
 From the data of a recent review, angiotensinogen, clusterin and thymidine 
phosphorylase were present only in “periodontal health”, whereas neutrophil defensin 1, 
carbonic anhydrase 1 andelongation factor-1 γ were more frequently present in “chronic 
periodontitis”. The number of proteins identified in GCF by proteomics may vary 
substantially, from dozens to hundreds, depending on the study design and statistical 
analysis. However, proteomics has not given definitive answers in periodontitis’ 
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pathogenesis, other than the fact that multiple, rather than single proteins have to be 
considered for efficient disease characterization (Bostanci 2018). 
 As far as metabolomic studies on the diagnostic value GCF for 
periodontitis, the metabolic pathway of purine degradation, which is a major source for 
reactive oxygen species production, was significantly accelerated in periodontitis patients 
(Barnes 2009). Putrescine, lysine, phenylalanine, ribose, taurine, 5-aminovaleric acid and 
galactose were identified to be higher in greater PDs (Ozeki 2016). From cross-sectional 
data, the following metabolites were associated with generalized aggressive periodontitis: 
noradrenaline, uridine, α-tocopherol, dehydroascorbic acid, xanthine, galactose, glucose 1-
phosphate and ribulose 5-phosphate (Chen 2018). 
A more recent study uracil, N-carbamylglutamate 2, N-acetyl-β-D-mannosamine 1, 
fructose 1, citramalic acid, 5-dihydrocortisol 3 and 4-hydroxyphenylacetic acid were 
associated with periodontitis while, thymidine 3 and O-phosphoserine 1 were associated 
with health (Pei 2020). Additionally, uric acid, hypoxanthine, glutathione and 
ergothioneine all seem to be downregulated in periodontitis-affected sites (Fornasaro 
2021). 
A recent systematic review and meta-analysis on GCF-identified metabolites 
concluded that oxidative stress-related metabolites are mainly associated with periodontitis 
(malondialdehyde, 8-hydroxy-deoxyguanosine, 4-hydroxynonenal and neopterin) were 
metabolite that has been associated with periodontitis, while periodontal health was linked 
to glutathione (Baima 2021). 
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Few studies have assessed the sensitivity and specificity of biomarkers in GCF as 
diagnostic tests. A recent systematic review and meta-analysis, which presented the highest 
level of evidence identified in the literature, reported the MMP-8 is the GCF biomarker 
with the highest sensitivity (76.7%) and excellent specificity (92%) (Arias-Bujanda 
2019). There is lack of metabolomic studies in the literature assessing sensitivity and 
specificity. This makes it the most consistent among the sum of GCF biomarkers to be 
possibly utilized in the diagnosis of periodontitis. 
Studies on the Prognostic Value of Gingival Crevicular Fluid for Periodontitis 
Over the years, multiple biomarkers have been identified in GCF as possible 
predictors of periodontitis’ initiation and progression. In a comparison between patients 
that had periodontal disease progression and stable ones, Metalloproteinases 8 and 9 
(MMP-8 & MMP-9), Osteoprotegerin (OPG) and Interleukin 1-β (IL-1β) were 
significantly higher in the periodontal disease progression group (Kinney 2014), and this 
was correlated with clinical measurements. MMP-8, which is in high concentration in 
patients with periodontitis has been shown to be one of the most reliable predictors of the 
periodontal disease onset and progression and may also be used as a monitoring agent in 
the periodontal maintenance periods, on a site-specific level (Leppilahti 2015). 
It seems that, along with MMP-8, IL-1β is one of the most-commonly found 
biomarker found in the GCF of periodontitis patients as well as one of the most well-studied 
predicting factors about progression of periodontal disease (Reinhardt 2010, Stadler 
2016). It has also been shown that their increase in periodontitis patients, compared to 
healthy individuals, correlates with an increase in the red and orange complex periodonto-
pathogenic bacteria, as described by Socransky in 1998 (Teles 2010). OPG, which is the 
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decoy receptor of RANKL, has, along with RANKL, also been detected in GCF and 
together they are known to play an important role in osteoclastic activity initiation and 
inhibition. Multiple other biomarkers have been identified in GCF as potential predictors 
of periodontitis initiation and progression with much less literature to support them. 
More definitive results were found with alkaline phosphatase, which has been 
identified as a biochemical marker with application in detection and progression of 
periodontitis (Sanikop 2012).  
Concluding from the available studies in the literature, identified metabolites in the 
GCF may be used as diagnostic tools for periodontal disease; even more they could be used 
in a site-specific manner. However, there is total lack of longitudinal metabolomic studies 
in the literature, investigating the value of metabolites as predictors of periodontal disease.  
Is there a way to use the metabolites that can be analyzed from the GCF to make a 
diagnostic and predictive test for periodontitis that is accurate and painless? It is the 
objective of this study to generate a prediction model capable of assigning any new GCF 
sample to the category of health or disease. Another aim of this project is to provide the 
tools to accurately predict disease initiation and disease progression before it shows clinical 
and radiographic signs in a site-specific manner as well as to identify the specific metabolic 
pathways that these metabolites are part of (pre-cursors and post-metabolites). 
We hypothesize that metabolites in gingival crevicular fluid through NMR and MS 
will predict future periodontal loss and distinguish between healthy and diseased sites. 
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Background: The technological advances in the field of metabolomics have shown 
promise for the development of a site-specific diagnostic test for periodontitis using the 
gingival crevicular fluid (GCF). We hypothesize that metabolites, identified through Mass 
Spectrometry (MS) will distinguish between health and disease.  
Methods: Ten stage III/IV periodontitis patients were recruited and ten healthy controls 
and GCF samples from the 6 Ramfjord teeth and 2 randomly selected sites were harvested 
from subjects with a porous silver disc. The samples were analyzed with Hydrophilic 
interaction liquid chromatography (HILIC) and reverse-phase liquid chromatography (RPLC)  
coupled with tandem MS.  Statistical analysis was performed using mixed linear models 
and the p-value was adjusted to control false discovery rate (FDR) using the method of 
Benjamini and Hochberg. Metaboanalyst 5.0 (www.metaboanalyst.ca) was utilized for 
pathway analysis. 
Results: 3,491 metabolites were identified from the sample analysis and 108 could be 
matched to existing libraries. Those metabolites can be statistically assigned (p<0.05) to 
12 human metabolic pathways. Butyric acid was associated healthy sites of healthy 
subjects, while Thymine, L-Theanine, Cytokinin B, L-Aspartic acid, D-Galactose, 
Citruline and Stachyose were associated with diseased sites of diseased subjects with an 
FDR <5%. The remaining identified compounds presented with a higher FDR. More 




Conclusion(s): GCF metabolites identified through MS could be a potential future means 
to diagnose periodontitis. Butyric acid was associated with periodontal health and thymine, 
L-theanine, Cytokinin B, L-aspartic acid, D-galactose, citrulline and stachyose were 
associated with periodontitis. Longitudinal comparisons and a larger sample could show 
value in the development of a predictive test/model as well.   
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1.  INTRODUCTION 
Periodontitis is characterized by microbially-associated, host-mediated inflammation that 
results in loss of periodontal attachment and its diagnosis is currently based on the use of 
the periodontal probe (Tonetti et. al. 2018). This instrument is utilized to conduct 
measurements in the dento-gingival sulcus in millimeters (mm). This is a rather 
rudimentary tool, which is uncomfortable for the patient and identifies periodontitis after 
it has developed.  It also entails measurement error (±1mm) by the examiner (Watts 1995). 
More contemporary tests that measure the periodontal microorganisms, proteins and 
enzymes in the periodontal pocket have low sensitivity and specificity to detect the 
progression or initiation of periodontal disease (Armitage 2003). Currently, there is no 
accurate way to predict the initiation and progression of periodontal disease. This is 
inefficient and expensive as an approach and it leads to unnecessary treatment for multiple 
patients. In 2015, the greatest losses in productivity were associated with tooth loss 
($126.67 billion – 67%) and severe periodontitis ($38.85 billion – 21%) (Righolt 2018). 
In an effort to create the specific diagnostic and prognostic test for periodontitis, oral fluids 
have been analyzed for potential biomarkers. The gingival crevicular fluid (GCF) is a 
physiological fluid and an inflammatory exudate which becomes inflammatory exudate in 
the presence of disease; thus, it has been used as a diagnostic aid since the 1970s (Golub 
1976, Smith 1977, Barros et. al 2016). 
The value of microbiological testing for periodontitis the different types of periodontal 
diseases is a subject of controversy and there is not a single one that has ideal characteristics 
(Sanz 2004). The “-omics” field shows promise in the development of an appropriate test 
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for the diagnosis, progression detection of periodontitis, as well as to determine the 
differential effects of treatment (Callif 2017).  
The genomic investigations identified few loci, mainly for aggressive and severe forms of 
the periodontitis, with most studies having small or moderate sample sizes and great 
heterogeneity (Morelli 2020). Usually, genomic and also transcriptomic studies have been 
focusing on one or limited candidate genes/transcripts. In these studies, classic 
inflammatory mediators have been identified (Trindale 2014). Proteomics is able to 
evaluate the complete protein and peptide in health and periodontitis. Proteomics has not 
yet given definitive answers in our understanding of the pathogenesis of periodontal 
disease, other than multiple, rather than single, proteins have to be considered for 
characterizing the disease efficiently (Bostanci 2018). In the 1990s, Smith is the one that 
starts to look into GCF proteomics in a site-specific way (Smith 1991, 1992). 
The most recent studies, however, focus on metabolomics, which has not yet been studied 
in equal detail to the previous three branches of the multi-omics (Veensra 2012). If we go 
back to the simplistic model of gene, transcript, protein and metabolite, our greatest chance 
in finding truly useful disease biomarkers will be studies that show correlation between 
biomolecules at all four levels. Metabolomics has gained popularity since it profiles 
directly the phenotype and changes thereof in contrast to other “-omics” technologies 
(Amberg 2017). Metabolomics’ ultimate aim is to obtain a complete screen of all the 
metabolites of a given biological sample and interpret how the metabolic profile changes 
with a given pathophysiological state.  
However, the technology to study metabolomics only recently reached its peak. The main 
techniques to study metabolomics are Mass Spectrometry (MS) and Nuclear Magnetic 
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Resonance (NMR) spectroscopy. NMR and MS both have their own advantages and 
disadvantages in conduction of metabolomic studies. MS’s greatest advantage is its high 
sensitivity, with the ability to detect numerous species in just one sample (Veenstra 2012, 
Emwas 2015). While, NMR is precise and unbiased, it has low sensitivity and cannot 
detect nearly as many compounds as MS does.  
While there are more studies on other fluids, such as saliva, serum and even studies on 
plaque, there are not enough studies on GCF yet (Takahashi 2010, Elabdeen 2013, 
Sakanaka 2017, Chen 2018).  
A recent systematic review investigating the diagnostic value of saliva samples 
metabolomics concluded that valine, phenylalanine, isoleucine, tyrosine and butyrate are 
increased in periodontitis-affected subjects, whereas lactate, pyruvate and N-acetyl groups 
were increased in periodontally healthy patients (Baima 2021). Additionally, salivary 
samples-detected metabolites cadaverine, 5-oxoproline, and histidine are associated with 
periodontitis and could potentially predict the onset and progression of that disease 
(Kuboniwa 2016). 
Whereas, saliva is more readily available compared to GCF, the latter has the advantage 
that it can reveal data on the metabolic profile on periodontitis in a site-specific way. A 
recent systematic review and meta-analysis on metabolites identified from GCF, came to 
the conclusion that oxidative stress-related metabolites are mainly associated with 
periodontitis (malondialdehyde, 8-hydroxy-deoxyguanosine, 4-hydroxynonenal and 
neopterin) were linked to periodontitis, whereas glutathione to periodontal health (Baima 




It is the aim of this study to generate a model capable of assigning any new GCF sample 
to the category of health or disease, in a site-specific manner. Additionally, to identify the 
specific metabolic pathways that these metabolites are part of (pre-cursors and post-
metabolites). We hypothesize that metabolites in gingival crevicular fluid identified 
through MS will distinguish between healthy and diseased sites. 
 
2. MATERIALS AND METHODS 
2.1 Study Design and Population 
Subjects with periodontitis and healthy controls that participated in this study were 
recruited at the University of Minnesota School of Dentistry in the time period of October 
2018 to January 2020. Upon performing a periodontal examination and screening visit, 
eligibility for the study was confirmed according to the inclusion and exclusion criteria. 
Written consent form and Health Insurance Portability and Accountability Act (HIPPA) 
forms were subsequently signed by the patient prior to the beginning of the study under 
University of Minnesota Institutional Review Board (IRB) protocol #1511M79922. 
Ten periodontally healthy subjects and 10 subjects with periodontitis were selected and 
recruited based on the 2017 World Workshop on the Classification of Periodontal and Peri‐
Implant Diseases and Conditions. The inclusion and exclusion criteria for the “test” and 




TABLE 1 Description of inclusion and exclusion criteria of the periodontitis (test) & healthy (control) groups 
 
Inclusion Criteria Exclusion Criteria 
Periodontitis (Test) Group 
Stage III or IV/Generalized Severe Periodontitis1 uncontrolled systemic diseases 
at least 5 teeth with CAL ≥ 5 mm systemic antibiotics within the last 3 months 
at least 1 site with PD ≥ 7 mm 
history of periodontal treatment or local 
antibiotics within the last 12 months 
≥ 33% of radiographic bone loss  
Healthy (Control) Group 
PD ≤ 3 mm uncontrolled systemic diseases 
CAL = 0 systemic antibiotics within the last 3 months 
no evidence of radiographic bone loss PD ≥ 4 mm 
 CAL ≥ 1 mm 
 evidence of radiographic bone loss 
 
1 Periodontitis classifications based of 2017 Workshop for a new classification of Periodontal and Peri-
implant Diseases and Conditions (Papapanou 2018) classification 
 
2.2 Clinical Examination and Sampling Technique  
All participants of the study were screened by residents or faculty of the Graduate 
Periodontology Clinic (Department of Developmental and Surgical Sciences) at the 
University of Minnesota. All involved investigators (M.C. – Primary Investigator, I.K. – 
Co-Investigator) underwent intra- and inter-examiner calibration for the measurement of 
PD and CAL.  
Every patient had full-mouth CAL and PD charted at the beginning of the study, with full-
mouth plaque, gingival bleeding and gingival index scores performed at all 6 sites (mesio-
buccal, straight-buccal, disto-buccal, mesio-lingual, straight-lingual, disto-lingual) of 
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existing teeth as a part of the screening process (O’Leary 1972, Newbrun 1996). After 
patient selection, according to inclusion and exclusion criteria, GCF samples were 
collected between 2 and 8 weeks from the screening visit. Six Ramfjӧrd teeth plus two 
additional teeth with the deepest pockets in the mouth were sampled for a total of 8 sites 
per patient (Ramfjord 1967).  At the sampling visit, proper isolation from salivary 
contamination was secured with a cotton roll or gauze.   Supragingival plaque was carefully 
removed with a curette, to avoid bleeding from the gingival margin or pushing 
supragingival plaque in the pocket.   The sulcus entrance was dried using a light stream of 
air from an air-water syringe directed away from the sulcus and towards the coronal aspect 
of the tooth.  A 50 μm thin porous (5 μm pores) silver disk 3.96 mm in diameter (Sterlitech 
[cat#AG5048]) was slid into the healthy gingival sulcus with cotton pliers until light 
resistance was felt for a total of 30 seconds.  Samples were discarded if visibly 
contaminated with blood, plaque or saliva. Saliva from the dorsal surface of the tongue was 
also sampled.  Subjects were asked to swallow excess saliva before placing the membrane 
on the dorsal side of the tongue for 30 seconds.  Two negative control samples, one with 
elution buffer alone and the other with an untouched silver disk plus buffer were also 
collected. Experimental and control samples were numbered sequentially throughout the 
study for experimental rigor to connect clinical measurements and metabolomic data for 
each samples site. Measurements were conducted using a Michigan probe with Williams 
markings (1-2-3-5-7-8-9-10 mm) (Hu-Friedy, IL, USA) with light to moderate pressure 
into the sulcus. PD was measured from the free gingival margin to the base of the pocket 
and CAL measurements were taken from the CEJ to the base of pocket or from a restorative 
margin to the base of pocket if the CEJ was not present. All sampled sites were checked 
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for presence or absence of plaque by sliding the probe supra-gingivally at the selected site.  
Bleeding on probing was assessed 30 seconds after probing and noted as profuse, pin-point 
or absent. Full-mouth measurements were taken as described in the screening visit and 
were collected again at the baseline visit only from the eight selected sites to obtain a 
“double set” of measurements.  Full-mouth peri-apical radiographs were taken at the 
beginning of the study and vertical bitewings were taken at the initial visit, using film 
holders with long cone paralleling, with phosphor plates or sensors. History of periodontal 
disease and new disease or extent of disease progression were measured as CAL change at 
each site. 
 
2.3 GCF sample processing  
At the sampling visit the silver disks were placed in an Eppendorf tube (TUBE A) and 
stored dry and frozen at -80 C within 4 hours.  At elution day, each silver disk was thawed, 
and 100 μL of Mass Spectrometry Grade water was added to each Eppendorf tube. Samples 
were vortexed for 30 seconds and centrifuged at 13,200 rpm (Microfuge-Eppendorf) for 1 
minute. Then the 100 μL solution was split into a 60 μL aliquot to submit for MS (TUBE 
B) and a 40 μL aliquot for NMR (TUBE C); TUBE C was stored as a part of an ongoing 
longitudinal investigation that includes comparison of MS with NMR. To the NMR sample 
aliquot, we added 10 μL of D20 (deuterium water) + 2,2-Dimethyl-2-silapentane-5-
sulfonic acid (DSS) [5x concentrated] + PBS [5x concentrated] + AZIDE [5x 
concentrated]. Following that, tubes B and C were frozen again at -80 C.  
Twenty-four hours prior to NMR analysis day, Tube C was thawed and immediately loaded 
in a borosilicate tube 1.7mm X 103.5 mm (SampleJet [cat #Z106462] – Bruker - Germany) 
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with long gel-loading pipet tips (Sorenson [Cat#: 13810]) and stored at +4°C. All samples 
were stored in a ~5°C refrigerator or cooled SampleJet sample changer at ~5°C while 
awaiting NMR acquisition.   
The thawed Eppendorf tube (TUBE B) was delivered to the Center of Mass Spectrometry 
and Proteomics (CMSP) lab in dry ice. The developed protocols of CMSP for processing 
of the sample followed the standards described in the current literature based on other 
biologic fluids (Bernini 2011, Dunn 2011, Dunn 2012, Broadhurst 2018). The protocol 
included: addition of heavy-atom (deuterated or 13C) and 4 volumes (400 μl) of chilled (-
20°C) 90/10 methanol/acetone to each sample. The samples were then vortexed at high 
speed for 1 min, incubated at -20°C for 15 min, centrifuged at 13,000 x g, 15 min, 4°C and 
transferred to new tubes.  Subsequently, the samples were evaporated to dryness under a 
stream of inert (nitrogen) gas and reconstituted in 5% acetonitrile, 0.1% formic acid, 
vortexed and centrifuged again (13,000 x g, 5 min, 4°C). The supernatants were then 
transferred to MS vials containing the indicated volume of 10% formic acid and stored at 
-70°C or -80°C until used for mass spectrometry. 
Hydrophilic interaction liquid chromatography (HILIC) was used which offers additional 
information to reverse-phase liquid chromatography (RPLC) by retaining polar metabolites 
(Contrepois 2015). HILIC is based on the hydrophilicity of the compound; non-polar 
compounds are detected first, followed by polar ones. On the contrary, RPLC is based on 
the hydrophobicity of the compound, with the most polar compounds being detected first, 
followed by the non-polar ones. Thus, with the combination of the two methods, the 
maximum number of compounds can be detected.  RPLC was run in a “positive” (observed 
ion has received a H+) and HILIC was run in a “negative” (observed ion has lost a H+) ion 
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mode. Available software – MZMine2 (Pluskal 2010) and XCMS (Smith 2006) – was 
used to process the MS-derived signal in order to achieve metabolite profiling. The 
metabolites were matched to available libraries: HMDB (Wishart 2008), the KEGG 
(Okuda 2008), NIST17 (Stein 2012) and MassBank (Horai 2010). The identified 
metabolites were submitted for pathway analysis to MetaboAnalyst 4.0 
(https://www.metaboanalyst.ca/) (Chong 2019). 
 
2.4 Statistical Analysis 
Prior to analysis, metabolite measurements (relative abundance) were normalized to total 
sample quantity by dividing each measurement by the total of all measurements in that 
sample. Next, each metabolite was log-transformed to have an approximately normal 
distribution, then centered and scaled to have mean 0 and standard deviation 1.  Each 
metabolite was then compared between the three groups (H/H, D/D, H/D) using mixed-
effects linear models, with a fixed effect for group and a random effect for participant to 
account for dependence among sites in the same participant.  To account for multiple 
comparisons of metabolites, p-values for these comparisons were adjusted, using the 
method of Benjamini and Hochberg (Benjamini 2015), to control the false discovery 
rate (FDR).  FDR is the expected proportion of false positive findings among all positive 
findings. Clustered image maps (heat maps) were used to visualize patterns among 
metabolite levels, sites, and groups, with metabolites and sites each ordered using 
hierarchical clustering to place similar metabolites or sites in close proximity.  PLS-DA 
was used to construct and examine the feasibility of a prediction model with group as the 
outcome and metabolites as predictors.  Analyses were conducted using R version 4.0.3 (R 
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Core Team 2020) including the packages lme4 version 1.1-26 (Bates 2015) and 
mixOmics version 6.12.2 (Rohart 2017). 
 
3. RESULTS 
A total of 20 subjects were recruited to the study. Of these subjects, 10 are test and 
10 are control subjects. In order to determine whether the membrane should be frozen dry 
or in PBS, a preliminary run was done. From the original pool of subjects, 4 samples were 
selected to be analyzed by Mass Spectrometry. 2 of these samples were stored dry, 
according to the above-described protocol and 2 were immersed in 60 μl of PBS and then 
frozen. From these samples, 14,801 metabolites were identified with Hydrophilic 
Interaction Liquid Chromatography (HILIC) coupled with tandem Mass Spectrometry. 
2,677 were matched to existing libraries and analyzed. 1,719 metabolites were better eluted 
from dry samples and 958 from wet samples, making elution from dry samples more 
suitable for analysis.  
12 metabolic pathways were found to be significantly associated with PD ≥4 mm 
(Fig. 1). The aminoacyl-tRNA biosynthesis pathway was associated with the greatest 
significance. The phenylalanine, tyrosine & tryptophan as well as the taurine and 
hypotaurine pathway had the greatest pathway impact when PD ≥4 mm; the increased 
pathway impact is associated with the number of metabolites which is observed in a 
specific metabolic pathway. Other pathways that were considered significant (P<0.05) 
were the following: arginine biosynthesis; alanine, aspartate and glutamate metabolism; D-
Glutamine and D-glutamate metabolism; Citrate cycle (TCA cycle); butanoate 
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metabolism; galactose metabolism; nitrogen metabolism; glyoxylate and dicarboxylate 
metabolism; histidine metabolism. The stratification of the samples in shallower [4-6 mm] 
and deeper [≥7 mm] pockets revealed the same significant pathways, but the level of 
significance was greater in the deeper pockets compared to the shallower ones.  
 
 
FIGURE 1 All matched significant pathways (p<0.05) from the pilot run are represented 
by circles, with the color of each circle corresponding to its p-value (y axis) and the size of 
the circle corresponding to its pathway impact value (x axis). The pathway impact depends 
on the number of metabolites that are seen in a specific metabolic pathway. 
 
Following the preliminary run, 220 samples were selected. 10 of which belonged 
to test individuals and 10 from healthy controls. All samples were randomized to assure 
that the individual conducting the MS processing is blind to which samples belongs to the 
test or control group. 402 compounds were detected with HILIC and 3,089 compounds 
were detected RPLC, indicating an expected superiority of RPLC in detecting a larger 
number of metabolites. Of the compounds identified with HILIC, only 42 metabolites 
could be initially identified and matched to existing libraries.  Similarly, of all the 
compounds detected with RPLC only 66 metabolites were identified and matched. 
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The metabolites identified by both RPLC and HILIC combined can be statistically 
assigned (p<0.05) to 12 human metabolic pathways (Fig. 2):  1. Aminoacyl-t-RNA 
biosynthesis; 2. arginine biosynthesis; 3. valine, leucine and isoleucine biosynthesis; 4. 
purine metabolism; 5. glycine, serine and threonine metabolism; 6. D-glutamine and D-
glutamate metabolism; 7. phenylalanine, tyrosine and tryptophan biosynthesis; 8. arginine 
and proline metabolism; 9. butanoate metabolism; 10. histidine metabolism; 11. alanine 
aspartate and glutamate metabolism; 12. pantothenate and CoA biosynthesis. The 
remaining 3,383 compounds remained un-matched, warranting a “targeted” approach to 




FIGURE 2 All matched significant pathways (p<0.05) from the untargeted RPLC and 
HILIC coupled with tandem MS are represented by circles, with the color of each circle 
corresponding to its p-value (y axis) and the size of the circle corresponding to its pathway 
impact value (x axis). The pathway impact depends on the number of metabolites that are 




From the untargeted approach of the positive run of MS volcano plots were made to 
represent comparisons among the groups of sites (Fig. 3). In the volcano plots each 
compound, identified and unidentified, is represented by a single, colored circle. The x axis 
represents the mean difference (the absolute difference between the mean value in the two 
compared groups) and the y-axis represents the FDR. A metabolite that is located far from 
0 on the x-axis has a greater difference in the means of the compared groups, while the +/- 
represents the group that the metabolite is associated with. The color of the circle represents 
the false discovery rate (FDR). The FDR is calculated based on adjusting the p-value 
adjusted using the method of Benjamini and Hochberg. The circles are large and colored 
pink, if FDR is <5% or significantly correlated with disease or with health, green and 
medium-sized if FDR=5-20%. The small and yellow circles represent an FDR >20%. The 
identified metabolites have their names written by their assigned circle. As seen, the 
majority of circles with FDR <5% were unidentified, indicating the necessity of a targeted 
approach. 
When metabolites in “healthy sites of healthy subjects” (H/H), were compared to 
metabolites in “diseased sites of diseased subjects” (D/D) (Fig. 3A) it appears that all the 
metabolites with a low FDR were not identified. However, Guanosine, Raffinose, Creatine, 
N-Nonanoylglycine and N-Deconoylglycine were positively associated with H/H, while 
Glyoylproline was positively associated with D/D with an FDR=5-20%.  
When metabolites H/H were compared to metabolites in “healthy sites of diseased 
subjects” (H/D) the metabolites Allopurinol riboside, N-Nonanoylglycine, Raffinose, 
Creatine, Pripionylcarnitine, L-Glutamine and Guanosine were positively associated with 
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H/H.  Metabolites (Fig. 3B).  No metabolites positively associated with H/D with 
FDR<20% were identified, and for both groups, all the metabolites with FDR<5% 
 remained unidentified, warranting a targeted approach.  
When metabolites in D/D were compared to metabolites in H/D there were only 2 detected 
metabolites positively associated with disease with an FDR<5%, both unidentified (Fig. 
3C). 5-Aminopentanoic acid, L-Proline, L-Aspartic acid, Putrescine, Glycosylproline, L-

















FIGURE 3 Volcano plots representing comparisons among predetermined groups having 
occurred from the MS in positive mode (untargeted).  3A Comparison of H/H vs. D/D. 3B 
Comparison of H/H vs. H/D.  3C Comparison of D/D vs. H/D 
(H/H): healthy sites of healthy subjects 
(D/D): diseased sites of diseased subjects 















FIGURE 3.  Volcano plots representing comparisons among predetermined groups having 
occurred from the RPLC-MS (untargeted). 3A Comparison of H/H vs. D/D. 3B 
Comparison of H/H vs. H/D. 3C Comparison of D/D vs. H/D 
In the volcano plots each compound, identified and unidentified, is represented by a single, 
colored circle. The circles are colored pink, if the false discovery rate (FDR) is <5%, green 
if FDR=5-20% and yellow if FDR >20%. The identified metabolites have their names 
written by their assigned circle. Most circles with FDR <5% were not identified. This 
indicates the need for a targeting approach. 
(H/H): healthy sites in healthy subjects; (D/D): diseased sites in diseased subjects;  
(H/D): healthy sites in diseased subjects 
  
3C Diseased in Diseased Healthy in Diseased 
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Similarly, HILIC-MS, volcano plots were made to represent comparisons among the 
groups of sites (Fig. 4). When metabolites in H/H, were compared to metabolites in D/D 
(Fig. 4A), Butyric acid was positively associated H/H and also Thymine, L-Theanine, 
Cytokinin B and Stachyose were positively associated with D/D with an FDR<5%. 
Expanding to an FDR=5-20%, N-Ortnithine-L-Taurine, Citrulline, Oxoglutaric acid, D-
Galactose, L-Aspartic acid, L-Proline, L-Methionine, L-Tryptophan, N-Methyl-1-
deoxynojirimycin, D-Ornithine, L-Phenylalanine, Alendronic acid, L-Tyrosine, L-Valine, 
L-Alanine, L-Leucine, Indole-3-propionic acid and N-Methyl-D-aspartic acid had positive 
associations with D/D. N-Decanoylglycine, N-Undecanoylglycine, N-Nonanoylglycine 
and Oleoyl glycine were positively associated with H/H with FDR=5-20%, 
When metabolites in H/H were compared to metabolites in H/D, the metabolite Butyric 
acid was positively associated with H/H, whereas Thymine and Cytokinin B were 
positively associated with H/D with an FDR=5-20% (Fig. 4B). This latter result indicates 
that H/D sites are more similar to D/D sites than to H/H sites.   Only 3 metabolites were 
detected with an FDR<5% for the group H/D and they all remained unidentified. 
When metabolites in D/D were compared to metabolites in H/D, L-Aspartic acid, D-
Galactose and Citruline were positively associated with D/D with an FDR<5% (Fig. 4C). 
Positively associated with D/D, with FDR=5-20% were: Thymine, N-Methy-D-Aspartic 
acid, Thymine, L-Theanine, Oxoglutaric acid, L-Methionine, L-Tryptophan, N-Methyl-1-
deoxynojirimycin, D-Ornithine, L-Alanine, N-Methyl-D-aspartic acid and L-Malic acid. 
Finally, Oleoylglycine and 6,7-Dihydro-4-(hydroxymethyl)-2-(p-hydroxyphenethyl)-7-

















FIGURE 4.  Volcano plots representing comparisons among predetermined groups having 
occurred from the HILIC-MS (untargeted). 4A Comparison of H/H vs. D/D. 4B 
Comparison of H/H vs. H/D. 4C Comparison of D/D vs. H/D 
In the volcano plots each compound, identified and unidentified, is represented by a single, 
colored circle. The circles are colored pink, if the false discovery rate (FDR) is <5%, green 
if FDR=5-20% and yellow if FDR >20%. The identified metabolites have their names 
written by their assigned circle. Most circles with FDR <5% were not identified. This 
indicates the need for a targeting approach. 
(H/H): healthy sites in healthy subjects; (D/D): diseased sites in diseased subjects;  
(H/D): healthy sites in diseased subjects 
4C 




A heatmap from the statistical analysis of the discovered metabolites grouped by subjects 
and sites, shows distinction from the top of the heatmap compared to the rest of it (Fig. 
5A). In this heatmap, the y-axis is a dendrogram that shows clustering of similar sites 
grouped together. The x-axis dendrogram shows clustering of the metabolites that have 
similar associations with one another. The dark red color in the heatmap represents low 
levels of a metabolite and the dark blue high levels of a metabolite. As indicated in the 
right of the heatmap, these rows correspond to the sites sampled from two particular 
subjects (#2 and #13). 
Similarly, from the PLS-DA analysis sites from subjects #2 and 13 appear quite differently 
from the ones from other subjects (Fig. 5B). The x-axis of the figure represents the single 
patient that samples derived from. The y-axis summarizes all the metabolites by a single 
score, with a higher score showing increased levels of the metabolites associated with 










FIGURE 5. (A) Heatmap representing the detected compounds in sampled sites from the 
selected 20 subjects. In the heatmap. The red color represents low levels of a metabolite 
and the blue high levels of a metabolite. (B) PLS-DA: Representation of each patient and 
the individual sampled sites. 
(H/H): healthy sites in healthy subjects (blue circle) 
(D/D): diseased sites in diseased subjects (red circle) 







In a similarly designed, unpublished study by the same group, using just NMR the number 
of metabolites that were identified was 35. As expected, the much more sensitive MS 
detected a much larger number of metabolites. In order to incorporate the benefits of NMR 
to the quantitive benefits of MS, this study was only a “pilot” component of an ongoing 
investigation. This investigation will conduct a targeted MS analysis of the existing “pilot” 
analysis to increase the sample size to 40 test and 40 control subjects; longitudinal 
comparisons analyzing the samples by both MS and NMR will be made as well with a total 
follow-up of 2 years.  
As the technologies of NMR and MS in metabolomics has just recently advanced, there 
still is a lack of studies in the literature. GCF can reveal the metabolic profile of 
periodontitis in a site-specific way. In the current literature, information on GCF 
metabolites associated with periodontitis is limited. In a study that compared GCF obtained 
from healthy, gingivitis and periodontitis subjects, the metabolic pathway of purine 
degradation, which is a major source for reactive oxygen species production, was 
significantly accelerated in periodontitis subjects (Barnes 2009). Metabolomic analysis 
through MS could be useful in prediction and diagnosis of the patient, showing distinct 
differences between healthy sites, shallower and deeper pockets, which is promising for 
the development of a new test (Ozeki 2016). Additionally, when extracting data from 
studies that utilized metabolomic analysis of both GCF and serum, more metabolites could 
be identified in the GCF (Chen 2018). In this study, both fluids could show significant 
differences between healthy and aggressive periodontitis subjects. 
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A recent study reported on the discovery of GCF metabolites associated with chronic 
periodontitis (Pei 2020). Uracil, N-carbamylglutamate 2, N-acetyl-β-D-mannosamine 1, 
fructose 1, citramalic acid, 5-dihydrocortisol 3 and 4-hydroxyphenylacetic acid. thymidine 
3 and O-phosphoserine 1 were associated with health. Analysis of GCF from periodontitis 
subjects using surface enhanced Raman scattering has led to the identification of uric acid, 
hypoxanthine, glutathione and ergothioneine, all of which were reduced in cases of 
periodontitis (Fornasaro 2021). 
A recent systematic review and meta-analysis from 15 studies on GCF metabolites, 11 of 
which were targeted, managed to identify a total of 10 metabolites with available 
information regarding their association with gingival health, gingivitis or periodontitis 
(Baima 2021). This study concluded that oxidative stress-related metabolites were 
primarily reported in association with periodontitis. Malondialdehyde, 8-hydroxy-
deoxyguanosine, 4-hydroxynonenal and neopterin were metabolite positively associated 
with periodontitis. Conversely, glutathione was positively associated with periodontal 
health. 
Salivary metabolites have also been studied as biomarkers for periodontitis. Cadaverine, 
5-oxoproline, and histidine have been shown to be metabolites isolated in saliva that are 
positively associated with periodontitis (Kuboniwa 2016). Other identified salivary 
metabolites associated with periodontal disease are the dipeptides leucylisoleucine, 
phenylphenol, and serylisoleucine as well as the fatty acids arachidonate, arachidate, and 
dihomo-linolate are attractive candidate markers (Barnes 2011). The bacterial metabolite 
phenylacetate isolated from saliva has been significantly associated with periodontitis as 
well, making a potential biomarker for periodontitis (Liebsch 2019). 
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Tongue swabs and saline washouts have been also able to identify metabolites that are 
related to health and disease through NMR analysis (Gawron 2019). Additionally, the 
salivary metabolic fingerprints, through NMR, of chronic and aggressive periodontitis have 
been studied with no significant differences between the two conditions (Romano 2018). 
Furthermore, an NMR-based study showed that non-surgical periodontal treatment is able 
to lead to significant changes in the salivary metabolic profile of a periodontitis patient; 
however, it will still be distinct from the one of a healthy patient (Romano 2019, Citterio 
2020). A recent systematic review on salivary metabolomics concluded that valine, 
phenylalanine, isoleucine, tyrosine and butyrate are increased in subjects with periodontitis 
(Baima 2021). Furthermore, that same study, found that lactate, pyruvate and N-acetyl 
groups were increased in periodontal health. 
Returning to our results, and as it occurs from the statistical analysis of the untargeted 
approach with RPLC- and HILIC-MS, it is evident that both methods are valuable in 
detecting a large number of metabolites. The pilot analysis of these 20 subjects was 
valuable for many reasons. To begin with, a targeted approach can now be started to 
identify the metabolites that appear with an FDR <5%.  This way, in future analyses of the 
samples to come, a targeted approach can be run from the start of the analysis. Secondly, 
it is established that the RPLC-MS provides a much larger number of metabolites compared 
to HILIC-MS. Additionally, there is a large number of metabolites that can clearly 
distinguish among the different groups as shown in Figures 5 and 6, thus suggesting that 
with the identification of these metabolites it is feasible to recognize a healthy site in a 
healthy patient, a diseased site in a diseased patient and a healthy site in a diseased patient 
from their metabolic “profile”. Possibly of all the comparisons, the most important one is 
44 
 
the one between H/D and D/D, as of all the sites, the H/D are the most susceptible to 
become D/D in the future.  It is interesting to follow-up the patients longitudinally to 
explore whether the changes in the metabolites correspond with disease progression. 
Finally, even from the limited number of metabolites identified with untargeted RPLC-MS 
and HILIC-MS (positive and negative mode), significant metabolic pathways could be 
identified (Figure 4). This is particularly promising considering that the targeted approach 
will identify a greater number of metabolites, significantly associated with health or 
disease, to be utilized for pathway analysis. 
 
5. CONCLUSION 
It appears that metabolites from the GCF of specific sites, identified through MS, 
are able to create a metabolic profile that can distinguish between health and disease. 
Butyric acid was positively associated with periodontal health whereas thymine, L-
theanine, cytokinin B, L-aspartic acid, D-galactose, citrulline and stachyose were 
associated with periodontitis.  This is promising because a diagnostic test can be developed 
in the future that can identify a healthy from a diseased site. Longitudinal comparisons 
pending, and with the recruitment of a larger sample of subjects, these data could also be 
of value in the development of a prognostic test as well. Additionally, it is promising, as 
suggested by the data acquired from this pilot analysis, to identify the specific metabolic 
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III. Extended Results 
 This project is part of an ongoing investigation focusing on the metabolites 
identified from the GCF in a site-specific manner. The subsequently presented results are 
a “pilot” presentation of the potential that MS spectrometry gives to this investigation. 
These results are deriving from analysis through MS of ten patients diagnosed with Stage 
III or IV periodontitis (test) and ten healthy controls and are analyzed only cross-
sectionally.   
 Additionally, as explained in the protocol of our study, these patients, along with 
30 more test and 30 more control subjects, are currently in 6-month follow-up protocol 
visit for re-sampling for a total of two years. It is expected that after MS and NMR the total 
sum of these samples is going to undergo the previously described longitudinal 
comparisons. 
 In a similarly designed, unpublished study by the same group, using just NMR the 
number of metabolites that were identified was 35. As expected, the much more sensitive 
MS detected a much larger number of metabolites in this branch of the study. However, 
there are results from this study that merit mention in our discussion. 
 Using data obtained from NMR analysis, we compared healthy sites in healthy 
subjects vs. diseased sites in diseased subjects, or healthy sites in healthy subjects’ disease 
vs. healthy sites in diseased subjects and diseased sites in diseased subjects vs. healthy sites 
in diseased subjects (Fig. 6). As expected, the biggest differences are represented in the 
comparison between healthy sites of healthy subjects vs. diseased sites in diseased patients. 
The confidence in these results is quite high, with the FDR set 0.05. Interestingly, healthy 
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sites in healthy patient did not show significant differences when compared to healthy sites 














FIGURE 6.  Volcano Plots of the baseline cross-sectional analysis by NMR 6A 
Comparison of H/H vs. D/D. 6B Comparison of H/H vs. H/D. 6C Comparison of D/D vs. 
H/D 
In the volcano plots each compound is represented by a single, dot. The dots are colored 
black if the FDR is <5% and white if FDR >5%. The identified metabolites have their 
names written by their assigned dot. 
(H/H): healthy sites in healthy subjects 
(D/D): diseased sites in diseased subjects 




Diseased in Diseased Healthy in Diseased 
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Furthermore, the yearly changes in metabolites over time with 95% confidence 
intervals were assessed and demonstrated in treated and untreated sites (Fig. 7).  This 
comparison was made to represent the changes in the metabolites before and after 
periodontal treatment.  The 95% confidence intervals for untreated are wide, potentially 
due to the small number of untreated patients in this group of that study, which does not 
allow for meaningful conclusions.  The few untreated sites, also possibly due to the small 
sample of patients, led to a high FDR. 
On the contrary, among the treated sites it is notable that decreases are observed in 
metabolites associated with periodontitis that were found in the baseline analysis (taurine, 
glucose, putrescine-lysine coherent resonances, cadaverine-lysine coherent resonances and 
propionate) and increases among some metabolites associated with health (uracil, creatine, 
methionine, isoleucine, aspartate, threonine, valine, arginine, trehalose). This means that, 
with treatment, metabolites that are associated with health increase, while metabolites 






FIGURE 7 Longitudinal (yearly) changes in metabolites with 95% confidence interval. 
Left column presents the untreated sites and the right column presents the treated sites. 
These results have been a part of the NMR analysis. The dots are colored red if the FDR is 
<20% and grey if FDR >20%. 
(H/H): healthy sites in healthy subjects 
(D/D): diseased sites in diseased subjects 




IV. Extended Discussion 
 Periodontitis is currently diagnosed and measured using the periodontal probe, a 
rudimentary and inaccurate in its measurements instrument (Armitage 2003, Listgarten 
1980, Isidor 1984, Van der Velden 1979-80). Within its disadvantages, the periodontal 
probe can only discover the existence and history of periodontitis after it is established. 
The use of current technological advances and particularly the field of “-omics” are 
showing great potential to develop a diagnostic and prognostic test in the future for 
periodontitis. The focus of the literature is currently on the field of metabolomics (Amberg 
2017).  
As the technologies of NMR and MS in metabolomics has just recently advanced, 
there is lack of studies in the published literature, particularly in GCF (Veentsra 2012, 
Emwas 2015, Schirra 2016, Barnes 2020). Currently, while there are more studies on 
other biologic fluids, such as saliva and serum, as well as studies on plaque, there are not 
enough studies on GCF yet. The majority of available studies is on salivary metabolites 
(Takahashi 2010, Elabdeen 2020, Mikkonen 2016, Sakanaka 2017, Chen 2018).  
Cadaverine, 5-oxoproline, and histidine have been shown to be metabolites isolated 
in saliva that are associated with periodontitis (Kuboniwa 2016). In the present study, 
cadaverine isolated from GCF samples is discovered with RPLC-MS and is positively 
associated with disease. Similarly, from our results from NMR analysis, cadaverine-lysine 
coherent resonances are associated with disease from cross-sectional data and gets reduced 
when periodontal therapy is performed.  
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Other identified salivary metabolites associated with periodontal disease are the 
dipeptides leucylisoleucine, phenylphenol, and serylisoleucine as well as the fatty acids 
arachidonate, arachidate, and dihomo-linolate are attractive candidate markers (Barnes 
2011). The bacterial metabolite phenylacetate isolated from saliva has been significantly 
associated with periodontitis as well, making a potential biomarker for periodontitis 
(Liebsch 2019). These compounds have not been identified through NMR in our project. 
It is possible that they have been detected through MS and remained unidentified; a 
targeted approach is required to confirm the presence or absence of such compounds in the 
GCF. 
A recent systematic review on salivary metabolomics concluded that valine, 
phenylalanine, isoleucine, tyrosine and butyrate are increased in subjects with periodontitis 
(Baima 2021). Furthermore, that same study, found that lactate, pyruvate and N-acetyl 
groups were increased in periodontal health. There are multiple contradictions among our 
results and the results of the Baima et. al. group, which could be attributed to the fact that 
our study’s results come from GCF, while the Baima et. al. systematic review presents 
results of saliva metabolites.  In contradiction with these results, butyric acid is positively 
associated with health and not periodontitis. In contrast to the results of this study, our GCF 
NMR-based project positively associated valine with health, rather than disease. Valine 
GCF levels identified through MS showed contradicting results among the different groups 
comparisons, being positively associated with both health and disease, while having a 
higher FDR.  Regarding the N-acetyl groups, the NMR component of our research shows 
a positive association of N-Acetylneuraminate with health, in agreement with the research 
group results by Baima et. al.  In yet another difference with the results obtained from 
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Baima et. al., while our MS results on GCF isoleucine levels were again contradictory 
among different groups comparisons, and linked to an FDR >20%, NMR managed to show 
a positive association with health. Regarding tyrosine, NMR showed increased tyrosine 
levels in healthy sites; however, MS contradicted these results by positively associating 
tyrosine with periodontitis, albeit with a higher FDR.  Additionally, MS analysis in GCF 
samples showed a weak association of phenylalanine with disease, on par with the results 
of Baima et. al. It is interesting to note that, in our study, GCF sample NMR analysis, 
detected significant lactate reduction in subjects after treatment of periodontitis, while 
isoleucine and valine levels seemed to increase after treatment. 
Additionally, the salivary metabolic fingerprints, through NMR, of chronic and 
aggressive periodontitis have been studied with no significant differences between the two 
conditions (Romano 2018). Confirming the results of the previous study, the profile of 
these two expressions of the disease shows increased proline, phenylalanine, and tyrosine 
and decreased levels of pyruvate, N-acetyl groups and lactate. Apart from the other 
metabolites that were previously discussed, proline as part of periodontal disease profile is 
confirmed by the MS results of our study. Surprisingly, NMR results strongly associates 
proline with periodontal health. Similar results from the same group are reported in a 
preceding study:  acetate, c-aminobutyrate, n-butyrate, succinate, trimethylamine, 
propionate, phenylalanine and valine, are positively associated chronic periodontitis, while 
pyruvate and N-acetyl groups were again positively associated with periodontal health 
(Aimetti 2012). Our results from GCF NMR analysis confirm the propionate increased 
levels in disease status. Furthermore, an NMR-based study showed that non-surgical 
periodontal treatment is able to lead to significant changes in the salivary metabolic profile 
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of a periodontitis patient, however it will still be distinct from the one of a healthy patient 
(Romano 2019, Citterio 2020).  
Another study managed to significantly relate periodontitis with the following 
metabolites in saliva: caproate, isocaproate/butyrate, isovalerate, isoleucine, 
isopropanol/methanol, 4-aminobutyrate, choline, sucrose, sucrose/glucose/lysine, 
lactate/proline, lactate and proline (Garcia-Villaescusa 2018). Of these metabolites, 
choline-related results from our NMR and MS studies are inconclusive on GCF. As far as 
sucrose, our NMR study has associated it with health, rather than disease, contradicting the 
above results.  
Tongue swabs and saline washouts have been also able to identify metabolites that 
are related to health and disease through NMR analysis (Gawron 2019). Tongue swabs 
revealed increased levels of isopropanol and reduced levels of glycerol in periodontitis 
subjects. Saline washouts revealed increased levels of lactate and decreased levels of 
acetone and methanol in periodontitis subjects. While the association identified for lactate 
in our study is previously mentioned in the manuscript, none of the other compounds 
identified by Gawron et.al could be identified by our study. Looking at results from another 
group, short chain fatty acids, such as butyrate were found increased in the saliva of patients 
with periodontitis; however, lactate, γ-amino-butyrate, methanol, and threonine were 
decreased (Rzenic 2017). Having discussed all the previously-mentioned metabolites, 
threonine, in our NMR study was positively and significantly associated with health, and 




Despite the fact that saliva is more readily available compared to GCF, the latter 
has the advantage that it can reveal data on the metabolic profile on periodontitis in a site-
specific manner. There is lack of literature currently on GCF metabolites associated with 
periodontitis. In a study that compared GCF obtained from healthy, gingivitis and 
periodontitis patients, the metabolic pathway of purine degradation, which is a major 
source for reactive oxygen species production, was significantly accelerated in 
periodontitis patients (Barnes 2009). Purine metabolism is a metabolic pathway that has 
been significantly associated with periodontitis, occurring from MS-analyzed data from 
our study.  
When extracting data from studies that utilized metabolomic analysis of both GCF 
and serum, more metabolites could be identified through GCF (Chen 2018).  In this study, 
both fluids could show significant differences between healthy and aggressive periodontitis 
patients. Focusing on the results from GCF, this study associated the following metabolites 
with generalized aggressive periodontitis: noradrenaline, uridine, α-tocopherol, 
dehydroascorbic acid, xanthine, galactose, glucose 1-phosphate and ribulose 5-phosphate. 
On the contrary, thymidine, glutathione and ribose 5-phosphate levels showed decrease in 
subjects with generalized aggressive periodontitis. Uridine has shown a trend for 
association with disease in the NMR branch our study, as it has increases in treated sites 
presenting with periodontal deterioration. Xanthine has been identified as a metabolite by 
MS in our study, however it presents inconclusive association with health or disease. D-
Galactose has shown a strong association with disease in our study HILIC-MS analysis.  
Metabolomic analysis through MS could be useful in prediction and diagnosis of 
the patient, showing distinct differences between healthy sites, shallower and deeper 
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pockets, which is promising for the development of a new test (Ozeki 2016).  Putrescine, 
lysine, phenylalanine, ribose, taurine, 5-aminovaleric acid and galactose were identified to 
be higher in greater PDs.  In our results from NMR, Putresine/Lysine coherent resonances 
were significantly associated with disease, while with treatment of the site, 
Putrecine/Lysine levels were significantly reduced. Additionally, cross-sectional data from 
MS confirm a trend for increase of putrescine in diseased site rather than the healthy sites 
of a diseased subject. MS results regarding lysine are inconclusive. As previously 
mentioned, MS results on phenylalanine show a weak trend for association with disease. 
While MS results on taurine are inconclusive, NMR showed a significant association with 
disease and a significant reduction in taurine after treatment of periodontitis, on par with 
the results of the above-mentioned study. This study by Ozeki et al. also showed a trend 
for increase on lactic acid, benzoic acid, glycine, malic acid, and phosphate with the 
increasing disease status of the patient. A similar trend for association with disease is also 
seen in our MS results for malic acid. 
A recent systematic review and meta-analysis from 15 studies on GCF metabolites, 
11 of which were targeted, managed to identify a total of 10 metabolites with available 
information regarding their association with gingival health, gingivitis or periodontitis 
(Baima 2021). This study concludes that oxidative stress-related metabolites are primarily 
reported in association with periodontitis. Malondialdehyde, 8-hydroxy-deoxyguanosine, 
4-hydroxynonenal and neopterin were metabolite that has been associated with 
periodontitis. Conversely, glutathione was associated with periodontal health. None of 
these metabolites have been identified through the MS or NMR in our projects. However, 
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the targeted approach of MS analysis remains to be conducted, potentially revealing some 
associations with these metabolites. 
A recent study reported on the discovery of GCF metabolites associated with 
chronic periodontitis (Pei 2020). Uracil, N-carbamylglutamate 2, N-acetyl-β-D-
mannosamine 1, fructose 1, citramalic acid, 5-dihydrocortisol 3 and 4-hydroxyphenylacetic 
acid. thymidine 3 and O-phosphoserine 1 were associated with health. The result of uracil 
contradicts NMR results from our study, as it is mostly associated with health; additionally, 
we showed that uracil increase can lead to increase in improved clinical measurements. 
MS cross-sectional results on uracil have been inconclusive. None of the other compounds 
have yet been identified in our study, using either NMR or MS. 
Analysis of GCF from periodontitis subjects using surface enhanced Raman 
scattering has led to the identification of uric acid, hypoxanthine, glutathione and 
ergothioneine, all of which were reduced in cases of periodontitis (Fornasaro 2021); 
however, uric acid results from our MS cross-sectional analysis are inconclusive. 
The untargeted RPLC-MS and HILIC-MS results show the value of MS in the 
detection of numerous metabolites. From our analysis it was concluded that a targeted 
approach is essential to identify more metabolites with an FDR <5%, which will also enrich 
our existing library of metabolites for pathway analysis. From the analysis, not only with 
MS, but also with NMR, specific metabolites could be identified to be positively associated 
with either health or disease. In this discussion, the NMR and MS results come from a 
different sample of subjects, which makes the results from the two different methods not 
directly comparable. To overcome this, the same MS-analyzed sites presented in this 
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manuscript will be also be analyzed with NMR. Follow-up of the same subjects for 2 years 
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